In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Paulus Kirchhof
Speaker
Paulus Kirchhof
Paulus Kirchhof Paulus Kirchhof

University Heart & Vascular Center Hamburg, Hamburg (Germany)

Specialities : Arrhythmias-General , Basic Science, Chronic Heart Failure, Myocardial Disease

https://www.uke.de/english/physicians-and-scientists/arztprofilseite_paulus_kirchhof.html

66 presentations from this speaker

Anticoagulation in patients with AHRE / SCAF: What do controlled trials tell us and what can we expect from ongoing studies?

Event : EHRA Essentials 4 You 2020

  • Session : Recent developments in risk stratification and early AF detection for the improved prevention of stroke and systemic embolic events
  • Speaker : P Kirchhof (Hamburg,DE)
  • Industry Essentials organised by Daiichi Sankyo Europe

Conclusions.

Event : ESC Congress 2020

  • Session : How evidence from routine clinical practice can improve the care of the elderly atrial fibrillation patient?
  • Speaker : P Kirchhof (Hamburg,DE)
  • Sponsored by Daiichi Sankyo Europe GmbH

Hot Line EAST - AFNET 4.

Event : ESC Congress 2020

  • Session : Hot Line EAST - AFNET 4
  • Speaker : B Casadei (Oxford,GB), S Priori (Pavia,IT), P Kirchhof (Hamburg,DE), TS Potpara (Belgrade,RS)

Panel discussion.

Event : ESC Congress 2020

  • Session : How evidence from routine clinical practice can improve the care of the elderly atrial fibrillation patient?
  • Speaker : R De Caterina (Pisa,IT), P Kirchhof (Hamburg,DE)
  • Sponsored by Daiichi Sankyo Europe GmbH

Presentation of the ESC Core Curriculum 2020.

Event : ESC Congress 2020

  • Session : ESC Core Curriculum 2020
  • Speaker : P Kirchhof (Hamburg,DE)

Arrhythmias – Drugs, ablation and devices.

Event : ESC Congress 2019

  • Session : The European Heart Journal’s advances in heart failure and valvular heart disease
  • Speaker : P Kirchhof (Hamburg,GB)
  • Joint with the European Heart Journal

Embolic stroke of undetermined source (ESUS) - Anticoagulation for everyone or search for atrial fibrillation?

Event : EHRA 2019

  • Session : Burning questions in stroke management
  • Speaker : P Kirchhof (Hamburg,GB)

State of the Art - Prediction of stroke and dementia in atrial fibrillation

Event : ESC Congress 2019

  • Session : Adverse outcomes in atrial fibrillation: can they be prevented?
  • Speaker : P Kirchhof (Hamburg,GB)

Two hours of subclinical atrial fibrillation - Start anticoagulation?

Event : EHRA 2019

  • Session : Knowledge gaps in anticoagulation for atrial fibrillation
  • Speaker : P Kirchhof (Hamburg,GB)

When should anticoagulation be stopped after atrial fibrillation ablation.

Event : ESC Congress 2019

  • Session : Challenging decision-making in anticoagulation therapy
  • Speaker : P Kirchhof (Hamburg,GB)

An atrial fibrillation patient needing combination antiarrhythmic drug treatment - What do the Guidelines say?

Event : ESC Congress 2018

  • Session : Atrial fibrillation: from Guidelines to clinical practice
  • Speaker : P Kirchhof (Edgbaston,GB)

Apixaban in patients undergoing atrial fibrillation ablation

Event : EHRA 2018

  • Session : Meet the Trialist - AXAFA-AFNET 5
  • Speaker : P Kirchhof (Edgbaston,GB)

Apixaban in patients undergoing atrial fibrillation ablation

Event : EHRA 2018

  • Session : Late-Breaking Trials
  • Speaker : P Kirchhof (Edgbaston,GB)

Balancing bleeding risk and effectiveness in patients requiring oral anticoagulation - State of the art

Event : ESC Congress 2018

  • Session : Bleeding risk and oral anticoagulation
  • Speaker : P Kirchhof (Edgbaston,GB)

Complementing results from randomised trials: the value of international observational studies.

Event : ESC Congress 2018

  • Session : Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Daiichi Sankyo

Conclusion - Summary: challenges and current insights for the management of atrial high rate episodes.

Event : EHRA 2018

  • Session : Challenges and current insights for the management of atrial high rate episodes
  • Speaker : P Kirchhof (Edgbaston,GB), A Goette (Paderborn,DE)
  • Organised by Atrial Fibrillation Network Association (AFNET), supported with an educational grant by Daiichi Sankyo

Device AF burden does not influence the decision to anticoagulate - CON

Event : EHRA 2018

  • Session : Burning issues in atrial fibrillation: device AF burden and the role of lifestyle changes
  • Speaker : P Kirchhof (Edgbaston,GB)

NOACs in Atrial Fibrillation (AF) patients undergoing cardiac procedures: what is the evidence?

Event : EHRA 2018

  • Session : NOACs in Atrial Fibrillation (AF) patients undergoing cardiac procedures: what is the evidence?
  • Speaker : A Alings (Breda,NL), P Kirchhof (Edgbaston,GB)
  • Sponsored by BMS Pfizer

Panel discussion.

Event : EHRA 2018

  • Session : Challenges and current insights for the management of atrial high rate episodes
  • Speaker : A Goette (Paderborn,DE), P Kirchhof (Edgbaston,GB)
  • Organised by Atrial Fibrillation Network Association (AFNET), supported with an educational grant by Daiichi Sankyo

Summary and close - Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice.

Event : ESC Congress 2018

  • Session : Oral anticoagulation in atrial fibrillation - From evidence-based medicine to daily clinical practice
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Daiichi Sankyo

Welcome and introduction - Challenges and current insights for the management of atrial high rate episodes.

Event : EHRA 2018

  • Session : Challenges and current insights for the management of atrial high rate episodes
  • Speaker : A Goette (Paderborn,DE), P Kirchhof (Edgbaston,GB)
  • Organised by Atrial Fibrillation Network Association (AFNET), supported with an educational grant by Daiichi Sankyo

Early cardioversion: is there strong evidence to support the concept?

Event : ESC Congress 2017

  • Session : Anticoagulation for cardioversion of atrial fibrillation: exploring areas of uncertainty
  • Speaker : P Kirchhof (Edgbaston,GB)

How can NOACs advance care of AF patients undergoing cardioversion?

Event : ESC Congress 2017

  • Session : Leading the way to improved stroke prevention with NOACs: focus on AF patients undergoing non-surgical procedures and on subclinical AF
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Incomplete evidence, gaps and uncertainties.

Event : EHRA 2017

  • Session : LAA occlusion workshop – How to sessions - Part I- Background
  • Speaker : P Kirchhof (Edgbaston,GB)

State of the Art: oral anticoagulation in the challenging patient

Event : ESC Congress 2017

  • Session : How to make oral anticoagulation safe
  • Speaker : P Kirchhof (Edgbaston,GB)

Stroke prevention in AF: which treatment for which patient?

Event : ESC Congress 2017

  • Session : Stroke prevention in atrial fibrillation (AF) and beyond ? Current guidelines and evolving concepts
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Organised by Charité Medical School, supported with an educational grant by the Translational Medicine Academy

The ESC vision on training and certification

Event : ESC Congress 2017

  • Session : European certification in cardiology: present & future
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Joint with the European Union of Medical Specialists (UEMS – EACCME)

The near future of precision medicine.

Event : EHRA 2017

  • Session : Innovations for better patient care: reports from the EHRA Innovation Forum
  • Speaker : P Kirchhof (Edgbaston,GB)

A case of persistent atrial fibrillation - Conclusion and take home message

Event : ESC Congress 2016

  • Session : New ESC Guidelines: when, what and how?
  • Speaker : P Kirchhof (Edgbaston,GB)

Atrial fibrillation

Event : ESC Congress 2016

  • Session : Meet the Guidelines Task Force - Atrial fibrillation
  • Speaker : P Kirchhof (Edgbaston,GB)

Atrial fibrillation - Part 1

Event : ESC Congress 2016

  • Session : ESC Guidelines 2016 - Overview
  • Speaker : P Kirchhof (Edgbaston,GB)

Characterising Atrial fibrillation by Translating its Causes into Health Modifiers in the Elderly (CATCH ME). How to apply for funding & succeed

Event : ESC Congress 2016

  • Session : European cardiovascular research and innovation – EU funding and networking opportunities
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Organised by EU

Ideal AF ablation candidate and when do I refer?

Event : ESC Congress 2016

  • Session : Creating a new landscape in AF ablation and the impact on clinical practice
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Medtronic

Introduction: Need for updated treatment strategies in atrial fibrillation.

Event : ESC Congress 2016

  • Session : Personalized treatment strategies for stroke prevention in atrial fibrillation - a perspective 5 years after ARISTOTLE
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Summary and take-home messages: edoxaban – A practical look at clinical applications.

Event : ESC Congress 2016

  • Session : Edoxaban – A practical look at clinical applications
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Daiichi Sankyo Europe GmbH

Welcome

Event : ESC Congress 2016

  • Session : What is new in the 2016 atrial fibrillation Guidelines?
  • Speaker : P Kirchhof (Edgbaston,GB)

Announcement by the chairpersons.

Event : ESC Congress 2015

  • Session : ESC William Harvey Lecture on Basic Science
  • Speaker : P Kirchhof (Edgbaston,GB)

Antithrombotic therapy.

Event : Heart Failure 2015

  • Session : Heart failure and atrial fibrillation: vicious twins
  • Speaker : P Kirchhof (Edgbaston,GB)

Atrial fibrillation detection in cryptogenic stroke patients: clinical evidences.

Event : EHRA 2015

  • Session : Atrial fibrillation and stroke in 2015
  • Speaker : P Kirchhof (Edgbaston,GB)

Catheter ablation in long term persistent atrial fibrillation.

Event : ESC Congress 2015

  • Session : Catheter ablation of atrial fibrillation: what should the clinician know?
  • Speaker : P Kirchhof (Edgbaston,GB)

European vs. American AF Guidelines.

Event : EHRA 2015

  • Session : Global approach to heart rhythm management
  • Speaker : P Kirchhof (Edgbaston,GB)

Future perspectives on stroke prevention in atrial fibrillation.

Event : ESC Congress 2015

  • Session : Non-vitamin K antagonist oral anticoagulants in atrial fibrillation – Translating trial data into clinical practice
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Daiichi Sankyo

Improving patient outcomes: how has the treatment landscape evolved?

Event : ESC Congress 2015

  • Session : Exploring the universe of oral anticoagulation in patients with non-valvular atrial fibrillation: continuing the journey
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by BMS-Pfizer Alliance

Non vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes. Design and rationale of the NOAH – AFNET 6 trial.

Event : EHRA 2015

  • Session : Atrial high rate episodes and stroke prevention – An update
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Organised by AFNET, supported by an unrestricted educational grant from Daiichi Sankyo Europe

Panel Discussion: non-vitamin K antagonist oral anticoagulants in atrial fibrillation – Translating trial data into clinical practice.

Event : ESC Congress 2015

  • Session : Non-vitamin K antagonist oral anticoagulants in atrial fibrillation – Translating trial data into clinical practice
  • Speaker : AJ Camm (London,GB), J Weitz (Hamilton,CA), H Heidbuchel (Antwerp,BE), RP Giugliano (Boston,US), P Kirchhof (Edgbaston,GB)
  • Sponsored by Daiichi Sankyo

What registries with oral anticoagulants are telling us.

Event : ESC Congress 2015

  • Session : A royal progression of NOACs
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by theheart.org / Medscape Education

Apixaban and interventional procedures in atrial fibrillation: what have we learnt and what will we learn?

Event : ESC Congress 2014

  • Session : Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Improving outcomes through early rhythm control therapy?

Event : ESC Congress 2014

  • Session : Closing the mortality gap in atrial fibrillation
  • Speaker : P Kirchhof (Edgbaston,GB)

Panel discussion: the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: are we getting there?

Event : ESC Congress 2014

  • Session : Overcoming the dilemma of stroke versus bleeding in non-valvular atrial fibrillation: can we optimise patient care with oral factor Xa inhibition
  • Speaker : G Montalescot (Paris,FR), A Goette (Paderborn,DE), J Alexander (Durham,US), P Kirchhof (Edgbaston,GB), S Connolly (Hamilton,CA)
  • Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Recommendations from the joint consensus document.

Event : ESC Congress 2014

  • Session : Warfarin or new anticoagulants in atrial fibrillation patients undergoing PCI
  • Speaker : P Kirchhof (Edgbaston,GB)

STAR AF 2: Discussant review

Event : ESC Congress 2014

  • Session : Hot Line: Heart failure: devices and interventions
  • Speaker : P Kirchhof (Edgbaston,GB)

STICS: Discussant review

Event : ESC Congress 2014

  • Session : Hot Line: Coronary artery disease and atrial fibrillation
  • Speaker : P Kirchhof (Edgbaston,GB)

Atrial fibrillation: risk scores, biomarkers, imaging, and genetics.

Event : ESC Congress 2013

  • Session : Towards a more personalised cardiology: outcomes of an ESC workshop. The role of 'personalised medicine' in...
  • Speaker : P Kirchhof (Edgbaston,GB)

Current treatment behaviours in Europe for stroke prevention in non-valvular atrial fibrillation.

Event : ESC Congress 2013

  • Session : Stroke prevention in non-valvular atrial fibrillation - Improving patient outcomes
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by the Bristol-Myers Squibb and Pfizer alliance

Economic aspects of atrial fibrillation.

Event : ESC Congress 2013

  • Session : Recent advances in the management of atrial fibrillation
  • Speaker : P Kirchhof (Edgbaston,GB)
  • Sponsored by Cardiome Pharma Development AG

Panel discussion.

Event : ESC Congress 2013

  • Session : Challenges in the management of atrial fibrillation
  • Speaker : R Cappato (Rozzano,IT), R Hobbs (Oxford,GB), P Kirchhof (Edgbaston,GB)

Panel discussion.

Event : ESC Congress 2013

  • Session : Challenges in the management of atrial fibrillation
  • Speaker : R Hobbs (Oxford,GB), E Hylek (Boston,US), P Kirchhof (Edgbaston,GB)

Presentation of the awardee.

Event : ESC Congress 2013

  • Session : ESC Rene Laennec Lecture on Clinical Cardiology
  • Speaker : P Kirchhof (Edgbaston,GB)

The left atrium: from development to atrial fibrillation.

Event : ESC Congress 2013

  • Session : Understanding atrial fibrillation: from molecules to treatment
  • Speaker : P Kirchhof (Edgbaston,GB)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are